POSTER SESSION IV
Tuesday, March 4, 2008   —  1:00 PM - 4:30 PM
Convention Center Exhibit Hall A


Click on the blue numbers in parentheses to display abstracts.
Click the button next to any title to add to Itinerary Planner...


BREAST PATHOLOGY



Poster#Title and AuthorsItinerary
Planner
1 Use of pHH3, Ki-67 and Survivin Immunoreactivity in the Evaluation of Fibroadenoma and Phyllodes Tumors of Breast (235)
SS Shah, OA El-Zammar - SUNY-Upstate Medical University, Syracuse, NY 		Add
2 Immunohistochemical Evaluation of Multiple Stromal Markers in Fibroadenoma and Phyllodes Tumor (270)
PJ Zhang, TL Pasha, G Acs - University of Pennsylvania Medical Center, Philadelphia, PA; H. Lee Moffitt Cancer Center, Tampa, FL 		Add
3 Comparison of Clinicopathologic Features and Prognosis between 17 Conventional Malignant Phyllodes Tumors and 5 Malignant Phyllodes Tumors with Liposarcomatous Transformation of the Breast (217)
Y Peng, KH Molberg - University of Texas Southwestern Medical Center, Dallas, TX 		Add
4 Interobserver Variability in Histological Grading of Invasive Mammary Carcinoma as a Function of Subspecialization (150)
O Hameed, AL Adams, HN Burford, NE Balmer, AC Baker, WC Bell, NC Jhala, T Winokur, MJ Klein, DC Chhieng - University of Alabama School of Medicine, Birmingham 		Add
5 Immunohistochemical Profile in Neuroendocrine Carcinoma of the Breast (112)
JY Dancer, HI Son, OJ Kosarac, GY Gong, SS Shen, QJ Zhai, A Ayala, JY Ro - The Methodist Hospital, Weill Medical College of Cornell University, Houston, TX; Asan Medical Center, Seoul, Korea 		Add
6 New Cutoff Points of Tumor Size Discriminates Patients' Survival Time More Precisely Than T Classification of the 6th AJCC Cancer Staging System of Breast Carcinoma (163)
SM Hong, H Cho, BY Choi, SH Kang, SJ Lee, YK Bae - The Johns Hopkins Medical Institutions, Baltimore, MD; Korea University, Seoul, Korea; Yeungnam University College of Medicine, Daegu, Korea 		Add
7 Is Acinic Cell Carcinoma a Variant of Secretory Carcinoma? A FISH Study Using ETV6 'Split Apart' Probes (224)
JS Reis-Filho, R Natrajan, R Vatcheva, MBK Lambros, C Marchio, B Mahler-Araujo, M Iravani, C Paish, Z Hodi, V Eusebi, IO Ellis - Institute of Cancer Research, London, United Kingdom; University of Nottingham, Nottingham, United Kingdom; Ospedalle Belaria, University of Bologna, Bologna, Italy 		Add
8 WT-1 Expression in Breast Carcinomas with Mucinous Morphology (230)
C Rowsell, WM Hanna, HJ Kahn - Sunnybrook Health Sciences Centre, University of Toronto, Canada 		Add
9 The Presence and Extent of Retraction Artifact and Micropapillary Features on Core Needle Biopsy Specimens Predict Lymph Node Metastasis in Breast Carcinoma (109)
S Chuang, G Paragh, PJ Zhang, G Acs - H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Pennsylvania Medical Center, Philadelphia, PA 		Add
10 Aplication of a Modified Gleason Score in Infiltrating Ductal Carcinoma of the Breast (221)
Y Quintero-Cuadra, AM Cano-Valdez, HR Dominguez-Malagon - Instituto Nacional de Cancerologia, Mexico City, Mexico 		Add
11 Percentage of High Risk Breast Lesions Upgraded after Core Biopsy: A Systematic Review and Meta-Analysis (187)
J Liu, B O'Hea, P Fisher, PB Kane, C Bernstein, C Tornos - Stony Brook University Medical Center, Stony Brook, NY 		Add
12 Needle Core Biopsy of Male Breast Avoids Surgical Excision in Appropriately Selected Clinicopathological Situations (123)
R Espinal-Witter, S Hoda - Weill Cornell Medical College, New York, NY 		Add
13 The Significance of Quantity and Histologic Pattern of Atypical Ductal Hyperplasia Diagnosed on Core Needle Biopsy of the Breast: Analysis of 118 Cases with Subsequent Excision (261)
MJ Wagoner, C Laronga, G Acs - H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 		Add
14 Assessment of 1183 Screen-Detected, "Probably Benign" Circumscribed Masses by Cytology and Core Biopsy with Long Term Follow Up Data (126)
G Farshid, P Downey, PG Gill, S Pieterse, BreastScreen SA Medical Specialists - BreastScreen SA, Adelaide, South Australia, Australia; Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia 		Add
15 FHIT and WWOX Expression Correlates with Hormone Receptor Status: A Tissue Microarray Study of 240 Breast Carcinomas (168)
RE Jimenez, S Costinean, R Pilarski, K Huebner, L Gentchev, C Shapiro - The Ohio State University, Columbus, OH 		Add
16 Atypical Ductal Hyperplasia in Core Biopsy: Are There Indictators of Upgrade at Excision? (129)
V Gasilionis, B Bolton, C Schiller, B Susnik - Northwestern Univ., Feinberg School of Medicine, Chicago 		Add
17 Clinico-Histopathological Correlation of Magnetic Resonance Image Guided Breast Core Biopsy: Institutional Review of Our Initial Experience (174)
MJ Kapadia, RF Brem, K Berezowski - The George Washington University Medical Center, Washington, DC 		Add
18 Clinical Significance of Pleomorphic Lobular Carcinoma In Situ on Core Needle Biopsies with Surgical Excisional Follow-Up (157)
DM Haynik, M Chivukula, A Brufsky, DJ Dabbs, G Carter - Magee Women's Hopsital, Pittsburgh, PA; Magee Women's Hospital, Pittsburgh, PA 		Add
19 Is p120 as Effective as E-Cadherin in Distinguishing Lobular from Ductal Carcinomas of the Breast? A Study of 235 Cases (100)
S Brandt, YB Chen, P Chadwick, SJ Shin - Weill Cornell Medical College, NY 		Add
20 In Situ and Invasive Carcinoma of the Female Breast Pre- and Post-Mammography (159)
DE Henson, AM Schwartz, H Nsouli, PM Grimley, WF Anderson - George Washington University, Washington, DC; USUHS, Bethesda, MD; NCI/NIH, Bethesda, MD 		Add
21 Is There Molecular Evidence for Progression of Microglandular Adenosis to Carcinoma: Results of Comparative Genomic Hybridization on Microdissected Lesions (242)
SJ Shin, PT Simpson, L Da Silva, J Mahalinga-Iyer, SR Lakhani, PP Rosen - Weill Cornell Medical College, New York, NY; School of Medicine, University of Queensland, Queensland Institute of Medical Research and Royal Brisbane & Women's Hospital, Brisbane, Australia 		Add
22 Podoplanin Expression in Myoepithelial Cells and Basal Cells in Breast and Prostate Tissue; Utility and Potential Pitfalls (173)
WA Kanner, KA Atkins - University of Virginia, Charlottesville, VA 		Add
23 What Is the Relationship between Closely Approximated Low-Grade Ductal and Lobular Lesions in the Breast? A Molecular Study of 10 Cases (260)
PL Wagner, N Kitabayashi, Y-T Chen, SJ Shin - Weill Cornell Medical College, New York, NY 		Add
24 Histologic Characterization of In-Situ Carcinoma in BRCA1 and BRCA2 Mutation Carriers without Invasive Disease: A Population-Based Study (228)
WM Rogers, AM Mulligan, A Bane, D West, I Andrulis, A Whittemore, FP O'Malley, E John, TA Longacre - Stanford University, Stanford, CA; Mount Sinai Hospital, Toronto, ON, Canada; NCCR, Fremont, CA 		Add
25 Characterization of Estrogen Receptor Positive Breast Cancers in BRCA1 Mutation Carriers (264)
Y Wang, L Collins, S Schnitt, J Garber, N Tung - Beth Israel Deaconess Medical Center, Boston; Dana Faber Cancer Institute, Boston; Harvard Medical School, Boston 		Add
26 BRCA1 and BRCA2-Associated Breast Cancers: Morphological and Immunohistochemical Differences (201)
AM Mulligan, AL Bane, D Pinnaduwage, IL Andrulis, FP O'Malley - Mount Sinai Hospital, Toronto, ON, Canada; St. Michael's Hospital, Toronto, ON, Canada 		Add
27 Breast Cancer Tumorigenic Cells Are Resistant to Chemotherapy (185)
X Li, MT Lewis, C Creighton, H Wong, MC Gutierrez, CK Osborne, SG Hilsenbeck, J Rosen, QJ Zhai, MR Schwartz, JC Chang - Baylor College of Medicine, Houston, TX; Methodist Hospital, Houston, TX 		Add
28 Comparison of Estrogen Receptor, Progesterone Receptor and Her-2 Status in Breast Cancer Pre- and Post-Neoadjuvant Chemotherapy (175)
M Kasami, T Uematsu, T Yabuzaki, H Sugimura - Shizuoka Cancer Center Hospital and Research Institute, Shimonagakubo Nagaizumi, Shizuoka, Japan; Hamamatsu Medical University School of Medicine, Hamamatsu, Shizuoka, Japan 		Add
29 The Influence of Hormone Receptor Status and HER1 and HER2 Expression on the Response to Neoadjuvant Therapy in Breast Cancer Patients (97)
L Bottiglieri, R Torrisi, G Pruneri, M Colleoni, G Viale - European Institute of Oncology, Milan, Italy 		Add
30 Pathological Response to Neoadjuvant Chemotherapy in the Triple Negative Breast Cancers in Our Patient Population (209)
GM Oprea-Ilies, ML Lund, L Yang, R O'Reagan, M Bouzyk, B Leyland-Jones, MB Mosunjac, SE Pambuccian, HE Gulbahce - Emory University, Grady Memorial Hospital, Atlanta, GA; Emory University, Atlanta, GA; University of Minnesota, Minneapolis, MN 		Add
31 Ex Vivo Predictive Biomarkers and Pharmacodynamic Assay in Breast Cancer (94)
PL Blanco, F Rojo, JM Corominas, S Menendez, A Dalmases, B Bellosillo, S Serrano - IMIM-Hospital del Mar, Barcelona, Spain 		Add
32 Does the Ki-67 Proliferation Index Complement the Oncotype DX® Recurrence Score? (147)
K Gwin, M Pinto, FA Tavassoli - Yale University School of Medicine, New Haven, CT 		Add
33 Experience with Oncotype DX at a Single Institution: Correlation with Histologic Tumor Features (181)
LP Kunju, CL Cookingham, M Banerjee, CG Kleer, DW Visscher - University of Michigan, Ann Arbor, MI 		Add
34 Molecular Profiling of BRCA1 and BRCA2-Associated Breast Cancers Identifies FGFR2 as a Gene Differentially Expressed in BRCA2-Associated Breast Cancers (87)
AL Bane, D Pinnaduwage, SB Bull, FP O'Malley, IL Andrulis - Mount Sinai Hospital, Toronto, ON, Canada; Samuel Lunenfeld Research Institute, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada 		Add
35 Fascin Expression Is Associated with Triple Negative (Basal-Like) Invasive Mammary Carcinoma and an Aggressive Phenotype (259)
P Vohra, O Pozdnyakova, M Prasad, A Khan - University of Massachusetts Medical School, Worcester, MA 		Add